PMID- 36796491 OWN - NLM STAT- MEDLINE DCOM- 20230321 LR - 20230627 IS - 1874-1754 (Electronic) IS - 0167-5273 (Linking) VI - 378 DP - 2023 May 1 TI - Novel biomarkers associated with thoracic aortic disease. PG - 115-122 LID - S0167-5273(23)00181-X [pii] LID - 10.1016/j.ijcard.2023.02.006 [doi] AB - BACKGROUND: Biomarkers might help to improve diagnosis, surveillance and risk stratification of thoracic aortic disease (TAD). We explored the association between a broad spectrum of cardiovascular biomarkers with clinical characteristics and thoracic aortic diameter in TAD patients. METHODS: Venous blood-samples were obtained in 158 clinically stable TAD patients visiting our outpatient clinic (2017-2020). TAD was defined as a thoracic aortic diameter >/= 40 mm, or genetic confirmation (hereditary TAD). The cardiovascular panel III of the Olink multiplex platform was used for batch analysis of 92 proteins. A comparison was made between biomarker levels in patients with and without previous aortic dissection and/or surgery, and with and without hereditary TAD. Linear regression analyses were applied to identify (relative, normalized) biomarker concentrations associated with the absolute thoracic aortic diameter (AD(max)), and thoracic aortic diameter indexed for body surface area (ID(max)). RESULTS: Median age of study patients was 61.0 (IQR 50.3-68.8) years, 37.3% females. Mean AD(max) and ID(max) were 43.3 +/- 5.4 mm and 21.3 +/- 3.3 mm/m(2). After multivariable adjustment, Matrix Metalloproteinase-3 (MMP-3) and Insulin-like growth factor binding protein 2 (IGFBP-2) showed a significant positive association with AD(max) and ID(max), respectively. Patients with previous aortic surgery/dissection had higher N-terminal-pro hormone BNP (NTproBNP) (median 3.67 [IQR 3.01-3.99] vs 2.84 [2.32-3.26], p